Covid-19 shows signs of revival in cases, government sources have assured that India has enough vaccine stockpile for its citizens and support exports to other countries if necessary.

About 1,010 active cases were recorded till 26 May, which reported new infections from Noida, Lucknow, Karnataka, Mumbai, Arunachal Pradesh and Varanasi, raising the concerns of another potential uptic.

Government sources told India Today that there is adequate store of covid -19 vaccines prepared for purification. Sources said, “We are fully prepared for any situation. We have enough reserves to meet the needs of our citizens. Also, if necessary, we can also supply vaccines to other countries,” the sources said.

Most of India, about 1 billion people, have received at least one dose of Kovishld or Kovaxin.

CovishIld, built by the Serum Institute of India (SII) under a license from Astrazneca, stopped its production in December 2021 due to reducing demand.

Similarly, Kovaxin, India’s first indigenous Kovid -19 vaccine, developed by India Biotech in collaboration with the Indian Medical Research – National Institute of Virology, stopped production in early 2022.

Despite the stop in manufacturing, officials say the availability of vaccine is not a matter of concern.

While doctors do this bounce for unexpected seasonal patterns of respiratory diseases, global health officials point to less safety from previous infections and vaccinations that can play a role in regional spikes.

In India, currently the major strains in circulation are LF.7, XFG, and JN.1, as well as the new Omikron sub-linage with nb.1.8.1.

These variants have overlapping symptoms that closely mimic normal flu: cough, nose, sore throat, low-grade fever, headache, body pain, and, in some cases, gastrointestinal crisis.

Although the seasonal behavior of Sars-Cov-2 now mirrors about other respiratory virus operated by periodic mutation, is a main difference: India’s existing vaccines were not designed to target these new sub-variants.

Despite this, health experts say that those who have already been infected or vaccinated, especially within the previous year, are still expected to maintain some protection against serious illness, even if they contracted a mutated version of the virus.

Whether India would need the update Covid-19 vaccine or not, remain under the evaluation. However, emerging research provides assurances.

A recent study by Arizona Health Sciences University, published in Nature Immunology, found that pre -vaccination provides strong immune protection, even against new variants such as delta and omikron.

Although it can reduce the body’s ability to generate variant-specific antibodies, vaccinated individuals still made a strong immune response than those who were never vaccinated.